Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability
Ribosomal proteins as unrevealed caretakers for cellular stress and genomic instability |
|
https://doi.org/10.18632/oncotarget.1784
Tae-Hyung Kim,
Patrick Leslie,
and Yanping Zhang
|
| 860-871 |
miR-34: from bench to bedside
miR-34: from bench to bedside |
|
https://doi.org/10.18632/oncotarget.1825
Massimiliano Agostini,
and Richard A. Knight
|
| 872-881 |
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma
Genome-wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma |
|
https://doi.org/10.18632/oncotarget.1801
Jie Li,
Shan Zhu,
David Kozono,
Kimberly Ng,
Diahnn Futalan,
Ying Shen,
Johnny C. Akers,
Tyler Steed,
Deepa Kushwaha,
Michael Schlabach,
Bob S. Carter,
Chang-Hyuk Kwon,
Frank Furnari,
Webster Cavenee,
Stephen Elledge,
and Clark C. Chen
|
| 882-893 |
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis
Role of aberrant PI3K pathway activation in gallbladder tumorigenesis |
|
https://doi.org/10.18632/oncotarget.1808
Andrea Lunardi,
Kaitlyn A. Webster,
Antonella Papa,
Bhavik Padmani,
John G. Clohessy,
Roderick T. Bronson,
and Pier Paolo Pandolfi
|
| 894-900 |
A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts
A novel peptide that inhibits E2F transcription and regresses prostate tumor xenografts |
|
https://doi.org/10.18632/oncotarget.1809
Xiaoqi Xie,
Nitu Bansal,
Tazeem Shaik,
John E. Kerrigan,
Tamara Minko,
Olga Garbuzenko,
Emine Ercikan Abali,
Nadine Johnson-Farley,
Debabrata Banerjee,
Kathleen W. Scotto,
and Joseph R. Bertino
|
| 901-907 |
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor |
|
https://doi.org/10.18632/oncotarget.1484
Russell T Burke,
Marc M Loriaux,
Kevin S Currie,
Scott A Mitchell,
Patricia Maciejewski,
Astrid S Clarke,
Julie A DiPaolo,
Brian J Druker,
Stephen E Spurgeon,
and Brian J Lannutti
|
| 908-915 |
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial |
|
https://doi.org/10.18632/oncotarget.1536
Aline Renneville,
Raouf Ben Abdelali,
Sylvie Chevret,
Olivier Nibourel,
Meyling Cheok,
Cecile Pautas,
Remy Dulery,
Thomas Boyer,
Jean-Michel Cayuela,
Sandrine Hayette,
Emmanuel Raffoux,
Hassan Farhat,
Nicolas Boissel,
Christine Terre,
Herve Dombret,
Sylvie Castaigne,
and Claude Preudhomme
|
| 916-932 |
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia
High Mdm4 levels suppress p53 activity and enhance its half-life in acute myeloid leukaemia |
|
https://doi.org/10.18632/oncotarget.1559
Ban Xiong Tan,
Kian Hoe Khoo,
Tit Meng Lim,
and David Philip Lane
|
| 933-943 |
Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer
Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.1458
Michelle X. Liu,
Michelle KY. Siu,
Stephanie S. Liu,
Judy WP. Yam,
Hextan YS. Ngan,
and David W. Chan
|
| 944-958 |
Engineered repressors are potent inhibitors of androgen receptor activity
Engineered repressors are potent inhibitors of androgen receptor activity |
|
https://doi.org/10.18632/oncotarget.1360
Greg N. Brooke,
Sue M. Powell,
Derek N. Lavery,
Jonathan Waxman,
Laki Buluwela,
Simak Ali,
and Charlotte L. Bevan
|
| 959-969 |
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer |
|
https://doi.org/10.18632/oncotarget.1630
Francesca Lovat,
Hideshi Ishii,
Monica Schiappacassi,
Matteo Fassan,
Mattia Barbareschi,
Enzo Galligioni,
Pierluigi Gasparini,
Gustavo Baldassarre,
Carlo M. Croce,
and Andrea Vecchione
|
| 970-977 |
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer
WNT-pathway components as predictive markers useful for diagnosis, prevention and therapy in inflammatory bowel disease and sporadic colorectal cancer |
|
https://doi.org/10.18632/oncotarget.1571
Annalucia Serafino,
Noemi Moroni,
Manuela Zonfrillo,
Federica Andreola,
Luana Mercuri,
Giuseppe Nicotera,
Joseph Nunziata,
Riccardo Ricci,
Armando Antinori,
Guido Rasi,
and Pasquale Pierimarchi
|
| 978-992 |
Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours
Post-transcriptional regulation of MRE11 expression in muscle-invasive bladder tumours |
|
https://doi.org/10.18632/oncotarget.1627
Rebecca M. Martin,
Martin Kerr,
Mark T.W. Teo,
Sarah J. Jevons,
Marianne Koritzinsky,
Bradly G. Wouters,
Selina Bhattarai,
and Anne E. Kiltie
|
| 993-1003 |
Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth
Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth |
|
https://doi.org/10.18632/oncotarget.1681
David Vindrieux,
Guillaume Devailly,
Arnaud Augert,
Benjamin Le Calve,
Mylene Ferrand,
Pascal Pigny,
Lea Payen,
Gerard Lambeau,
Michael Perrais,
Sebastien Aubert,
Hélène Simonnet,
Robert Dante,
and David Bernard
|
| 1004-1013 |
Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity
Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity |
|
https://doi.org/10.18632/oncotarget.1629
Jakob H. Mikkelsen,
Zachary T. Resch,
Bhanu Kalra,
Gopal Savjani,
Ajay Kumar,
Cheryl A. Conover,
and Claus Oxvig
|
| 1014-1025 |
SCFβ-TRCP-mediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway
SCFβ-TRCP-mediated degradation of NEDD4 inhibits tumorigenesis through modulating the PTEN/Akt signaling pathway |
|
https://doi.org/10.18632/oncotarget.1675
Jia Liu,
Lixin Wan,
Pengda Liu,
Hiroyuki Inuzuka,
Jiankang Liu,
Zhiwei Wang,
and Wenyi Wei
|
| 1026-1037 |
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR |
|
https://doi.org/10.18632/oncotarget.1637
Ulrike M. Litzenburger,
Christiane A. Opitz,
Felix Sahm,
Katharina J. Rauschenbach,
Saskia Trump,
Marcus Winter,
Martina Ott,
Katharina Ochs,
Christian Lutz,
Xiangdong Liu,
Natasa Anastasov,
Irina Lehmann,
Thomas Höfer,
Andreas von Deimling,
Wolfgang Wick,
and Michael Platten
|
| 1038-1051 |
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene |
|
https://doi.org/10.18632/oncotarget.1697
Erling A. Hoivik,
Kanthida Kusonmano,
Mari K. Halle,
Anna Berg,
Elisabeth Wik,
Henrica M. J. Werner,
Kjell Petersen,
Anne M. Oyan,
Karl-Henning Kalland,
Camilla Krakstad,
Jone Trovik,
Martin Widschwendter,
and Helga B. Salvesen
|
| 1052-1061 |
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer |
|
https://doi.org/10.18632/oncotarget.1760
Shigeru Kawabata,
Chun-Te Chiang,
Junji Tsurutani,
Hideaki Shiga,
Matthew L. Arwood,
Takefumi Komiya,
Joell J. Gills,
Regan M. Memmott,
and Phillip A. Dennis
|
| 1062-1070 |
SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade
SENP5 mediates breast cancer invasion via a TGFβRI SUMOylation cascade |
|
https://doi.org/10.18632/oncotarget.1783
Rivki Cashman,
Helit Cohen,
Rotem Ben-Hamo,
Alona Zilberberg,
and Sol Efroni
|
| 1071-1082 |
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1
miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1 |
|
https://doi.org/10.18632/oncotarget.1804
Zuoren Yu,
Zengguang Xu,
Gabriele DiSante,
Jennifer Wright,
Min Wang,
Yuan Li,
Qian Zhao,
Tao Ren,
Xiaoming Ju,
Ellen Gutman,
Guangxue Wang,
Sankar Addya,
Tieyan Li,
Zhendong Xiang,
Chenguang Wang,
Xiongfei Yang,
Xiaolai Yang,
and Richard Pestell
|
| 1083-1090 |
HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation
HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation |
|
https://doi.org/10.18632/oncotarget.1787
Charles Cobbs,
Sabeena Khan,
Lisa Matlaf,
Sean McAllister,
Alex Zider,
Garret Yount,
Kenneth Rahlin,
Lualhati Harkins,
Vladimir Bezrookove,
Eric Singer,
and Liliana Soroceanu
|
| 1091-1100 |
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity
Functional analysis of MKP-1 and MKP-2 in breast cancer tamoxifen sensitivity |
|
https://doi.org/10.18632/oncotarget.1795
Kelly K. Haagenson,
Jessica Wei Zhang,
Zhengfan Xu,
Malathy P.V. Shekhar,
and Gen Sheng Wu
|
| 1101-1115 |
